With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.
U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
It's summer, when few are thinking about the coming influenza threat. But top vaccine makers are already kicking off their flu shot shipments.
VBI Vaccines hopes to challenge the hepatitis B vaccine standard-of-care, a position long held by GlaxoSmithKline’s Engerix-B.
Hundreds of Takeda employees in R&D and vaccines have relocated from suburban Chicago to the Boston area, according to a new report.
Emergent BioSolutions has snapped up the only FDA-approved smallpox vaccine from Sanofi Pasteur.
After taking a beating in countless press reports over its Zika vaccine partnership with the U.S. Army, Sanofi is hoping to clear the air.
GlaxoSmithKline plans to explore MenB vaccine Bexsero's potential in preventing gonorrhea after a new study suggested plausible protection.
Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
After fears that President Trump may push for a change in vaccine policy, Fitzgerald's appointment will likely be a relief to medical professionals.